- Home
- LCTX vs RAPT Comparison
LCTX vs RAPT Comparison
Compare LCTX & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- RAPT
- Stock Information
- Founded
- LCTX 1990
- RAPT 2015
- Country
- LCTX United States
- RAPT United States
- Employees
- LCTX N/A
- RAPT N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- LCTX Health Care
- RAPT Health Care
- Exchange
- LCTX Nasdaq
- RAPT Nasdaq
- Market Cap
- LCTX 107.3M
- RAPT 122.9M
- IPO Year
- LCTX N/A
- RAPT 2019
- Fundamental
- Price
- LCTX $1.00
- RAPT $9.86
- Analyst Decision
- LCTX Strong Buy
- RAPT Buy
- Analyst Count
- LCTX 5
- RAPT 5
- Target Price
- LCTX $4.20
- RAPT $32.20
- AVG Volume (30 Days)
- LCTX 1.6M
- RAPT 98.9K
- Earning Date
- LCTX 08-12-2025
- RAPT 08-19-2025
- Dividend Yield
- LCTX N/A
- RAPT N/A
- EPS Growth
- LCTX N/A
- RAPT N/A
- EPS
- LCTX N/A
- RAPT N/A
- Revenue
- LCTX $9,557,000.00
- RAPT N/A
- Revenue This Year
- LCTX N/A
- RAPT N/A
- Revenue Next Year
- LCTX $244.95
- RAPT N/A
- P/E Ratio
- LCTX N/A
- RAPT N/A
- Revenue Growth
- LCTX 19.42
- RAPT N/A
- 52 Week Low
- LCTX $0.37
- RAPT $5.67
- 52 Week High
- LCTX $1.21
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- LCTX 50.84
- RAPT 47.87
- Support Level
- LCTX $1.00
- RAPT $10.10
- Resistance Level
- LCTX $1.09
- RAPT $13.50
- Average True Range (ATR)
- LCTX 0.08
- RAPT 1.01
- MACD
- LCTX -0.02
- RAPT -0.32
- Stochastic Oscillator
- LCTX 24.25
- RAPT 5.61
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.